Castle Biosciences
Stock Forecast, Prediction & Price Target
Castle Biosciences (CSTL) stock Price Target by analysts
$40.4
Potential upside: 103.01%
Castle Biosciences price prediction
What is Castle Biosciences stock analysts` prediction?
Castle Biosciences stock forecast: Based on 4 Wall Street analysts` predicted price targets for Castle Biosciences in the last 3 months, the avarage price target is $40.4, with a high forecast of $NaN. The average price target represents a 103.01% change from the last price of $19.9.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Castle Biosciences stock Price Target by analysts
Full breakdown of analysts given Castle Biosciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Sung Ji Nam BTIG | 0% 0/3 | 10 months ago | $45 126.13% upside | $31.15 | StreetInsider | Previous targets (2) |
Catherine Schulte Robert W. Baird | 0% 0/1 | 10 months ago | $39 95.97% upside | $32.8 | StreetInsider | Previous targets (0) |
Paul Knight KeyBanc | 0% 0/1 | 10 months ago | $36 80.90% upside | $32.8 | StreetInsider | Previous targets (0) |
Kyle Mikson Canaccord Genuity | 0% 0/1 | 10 months ago | $42 111.05% upside | $32.4 | StreetInsider | Previous targets (0) |
Sung Ji Nam BTIG | 0% 0/3 | 11 months ago | $40 101.00% upside | $31.31 | StreetInsider | Previous targets (2) |
Sung Ji Nam BTIG | 0% 0/3 | about 1 year ago | $35 75.87% upside | $26.24 | StreetInsider | Previous targets (2) |
Catherine Schulte Analyst Robert W. Baird | 0% 0/1 | almost 3 years ago | $41 106.03% upside | $24.72 | Benzinga | Previous targets (0) |
Castle Biosciences Financial Estimates
Castle Biosciences Revenue Estimates
Castle Biosciences EBITDA Estimates
Castle Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $94.08M N/A | $137.03M 45.65% | $219.78M 60.38% | Avg: $261.28M Low: $254.89M High: $265.10M avg. 18.87% | Avg: $297.43M Low: $290.15M High: $301.78M avg. 13.83% | Avg: $325.45M Low: $317.49M High: $330.20M avg. 9.42% | Avg: $358.95M Low: $350.17M High: $364.19M avg. 10.29% |
Net Income
% change YoY
| $-31.29M N/A | $-67.13M -114.55% | $-57.46M 14.40% | Avg: $-51.81M Low: $-82.01M High: $-27.87M avg. 9.82% | Avg: $-19.76M Low: $-63.78M High: $-4.82M avg. 61.85% | Avg: $-6.56M Low: $-6.69M High: $-6.35M avg. 66.77% | Avg: $8.44M Low: $8.17M High: $8.60M avg. 228.57% |
EBITDA
% change YoY
| $-36.60M N/A | $-76.63M -109.35% | $-45.02M 41.24% | Avg: $-62.43M Low: $-63.34M High: $-60.90M avg. -38.66% | Avg: $-71.06M Low: $-72.10M High: $-69.33M avg. -13.83% | Avg: $-77.76M Low: $-78.90M High: $-75.86M avg. -9.42% | Avg: $-85.76M Low: $-87.02M High: $-83.67M avg. -10.29% |
EPS
% change YoY
| -$1.24 N/A | -$2.58 -108.06% | -$2.14 17.05% | Avg: -$1.91 Low: -$3.06 High: -$1.04 avg. 10.85% | Avg: -$1.13 Low: -$2.38 High: -$0.18 avg. 40.76% | Avg: -$0.25 Low: -$0.25 High: -$0.24 avg. 78.31% | Avg: $0.32 Low: $0.3 High: $0.32 avg. 228.57% |
Operating Expenses
% change YoY
| $118.34M N/A | $196.17M 65.76% | $242.78M 23.76% | Avg: $215.46M Low: $210.19M High: $218.61M avg. -11.25% | Avg: $245.27M Low: $239.27M High: $248.85M avg. 13.83% | Avg: $268.37M Low: $261.81M High: $272.30M avg. 9.42% | Avg: $296.00M Low: $288.76M High: $300.33M avg. 10.29% |
FAQ
What is Castle Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 91.75% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -82.01M, average is -51.81M and high is -27.87M.
What is Castle Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 13.10% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $254.89M, average is $261.28M and high is $265.10M.
What is Castle Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 89.62% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$3.06, average is -$1.91 and high is $-1.04.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Castle Biosciences stock. The most successful analyst is Sung Ji Nam.